Drugs that contain Ixazomib Citrate

1. Drug name - NINLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 10 months from now)

US8003819 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8530694 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US7687662 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8859504 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

US7442830 TAKEDA PHARMS USA Proteasome inhibitors
Nov, 2029

(7 years from now)

CN102066386A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Apr, 2014

(8 years ago)

CN103497232A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jan, 2016

(6 years ago)

CN103497210A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Dec, 2017

(4 years ago)

CN103435638A TAKEDA PHARMS USA Ester Compound And Pharmaceutical Compositions Thereof
Feb, 2018

(4 years ago)

CN103450241A TAKEDA PHARMS USA Borate Ester Compound And Pharmaceutical Compositions Thereof
Mar, 2018

(4 years ago)

CN103467565A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Sep, 2018

(4 years ago)

CN1867572B TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN1867572A TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN101772507B TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN102961387B TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN105837608A TAKEDA PHARMS USA Proteasome Inhibitor And Composition And Application Thereof
Aug, 2027

(4 years from now)

CN105837608B TAKEDA PHARMS USA Proteasome Inhibitors And Compositions And Uses Thereof
Aug, 2027

(4 years from now)

CN102961387A TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN101772507A TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

IN231455B TAKEDA PHARMS USA Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation .
Aug, 2024

(1 year, 10 months from now)

IN200600565P2 TAKEDA PHARMS USA Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation
Aug, 2024

(1 year, 10 months from now)

IN290327B TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

IN201100107P1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

IN201000939P1 TAKEDA PHARMS USA Proteasome Inhibitors
Feb, 2030

(7 years from now)

IN295244B TAKEDA PHARMS USA Proteasome Inhibitors
Feb, 2030

(7 years from now)

EP2730581B1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jul, 2017

(5 years ago)

EP2730581A1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jul, 2017

(5 years ago)

EP1660507B1 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507A2 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507B2 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507B9 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP2178888B1 TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

EP2178888A1 TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

EP2318419B1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

EP2318419A1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same Aug, 2024

(1 year, 10 months from now)

US8871745 TAKEDA PHARMS USA Proteasome inhibitors Aug, 2027

(4 years from now)

US9175017 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof Jun, 2029

(6 years from now)

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.3MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.